

Antonio Llinas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9393624/publications.pdf>

Version: 2024-02-01

33
papers

1,809
citations

430754

18
h-index

414303

32
g-index

34
all docs

34
docs citations

34
times ranked

2916
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxadiazoles in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1817-1830.	2.9	458
2	Polymorph control: past, present and future. <i>Drug Discovery Today</i> , 2008, 13, 198-210.	3.2	284
3	Solubility Challenge: Can You Predict Solubilities of 32 Molecules Using a Database of 100 Reliable Measurements?. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 1289-1303.	2.5	166
4	Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3667-3677.	2.9	111
5	Diclofenac Solubility: An Independent Determination of the Intrinsic Solubility of Three Crystal Forms. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 979-983.	2.9	109
6	Predicting Intrinsic Aqueous Solubility by a Thermodynamic Cycle. <i>Molecular Pharmaceutics</i> , 2008, 5, 266-279.	2.3	104
7	Equilibrium solubility measurement of ionizable drugs – consensus recommendations for improving data quality. <i>ADMET and DMPK</i> , 2016, 4, 117.	1.1	78
8	Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1785-1799.	2.9	54
9	Intramolecular general acid catalysis in the aminolysis of β -lactam antibiotics. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 651-654.	1.5	45
10	A new method for the reproducible generation of polymorphs: two forms of sulindac with very different solubilities. <i>Journal of Applied Crystallography</i> , 2007, 40, 379-381.	1.9	44
11	Discovery of AZD6642, an Inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the Treatment of Inflammatory Diseases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 897-911.	2.9	39
12	Solubility Challenge Revisited after Ten Years, with Multilab Shake-Flask Data, Using Tight (SD \approx 0.17) Tj ETQq0 0 0 rgBT /Overlock 10 3036-3040.	2.5	37
13	Potent and Orally Bioavailable Inverse Agonists of ROR γ t Resulting from Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7796-7813.	2.9	31
14	Findings of the Second Challenge to Predict Aqueous Solubility. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4791-4803.	2.5	31
15	Concomitant Hydrate Polymorphism in the Precipitation of Sparfloxacin from Aqueous Solution. <i>Crystal Growth and Design</i> , 2008, 8, 114-118.	1.4	27
16	Fast and General Method To Predict the Physicochemical Properties of Druglike Molecules Using the Integral Equation Theory of Molecular Liquids. <i>Molecular Pharmaceutics</i> , 2015, 12, 3420-3432.	2.3	22
17	Chemical Reactivity of Penicillins and Cephalosporins. Intramolecular Involvement of the Acyl-Amido Side Chain. <i>Journal of Organic Chemistry</i> , 1998, 63, 9052-9060.	1.7	21
18	Impact of Input Parameters on the Prediction of Hepatic Plasma Clearance Using the Well-Stirred Model. <i>Current Drug Metabolism</i> , 2010, 11, 583-594.	0.7	20

#	ARTICLE	IF	CITATIONS
19	Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 972-977.	1.3	16
20	Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9705-9730.	2.9	14
21	Amodiaquinium dichloride dihydrate from laboratory powder diffraction data. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2006, 62, o4196-o4199.	0.2	13
22	Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5974-5987.	2.9	13
23	Membrane Permeability in Cyclic Peptides is Modulated by Core Conformations. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 263-269.	2.5	13
24	Two New Polymorphic Cocrystals of Zafirlukast: Preparation, Crystal Structure, and Stability Relations. <i>Crystal Growth and Design</i> , 2015, 15, 4162-4169.	1.4	9
25	Multisolvant Models for Solvation Free Energy Predictions Using 3D-RISM Hydration Thermodynamic Descriptors. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 2977-2988.	2.5	9
26	The role of a $\hat{\text{I}}^2$ -proton transfer donor in the degradation of benzylpenicillin. <i>Journal of Molecular Catalysis A</i> , 2001, 175, 3-16.	4.8	8
27	Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5557-5561.	1.0	7
28	AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13807-13829.	2.9	7
29	Property prediction and pharmacokinetic evaluation of mixed stoichiometry cocrystals of zafirlukast, a drug delivery case study. <i>CrystEngComm</i> , 2018, 20, 1346-1351.	1.3	6
30	The Solid State Landscape of the Sildenafil Drug. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1104-1109.	1.6	6
31	Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 119-124.	1.0	5
32	Derisking Development by a Cocrystallization Screen of a Novel Selective Inhaled JAK-STAT inhibitor. <i>Crystal Growth and Design</i> , 2019, 19, 403-414.	1.4	2
33	Strategies of solubility enhancement and perspectives in solubility measurements of pharmaceutical compounds. <i>ADMET and DMPK</i> , 2020, 8, 176-179.	1.1	0